Previous Article | Next Article ![]()
Infection and Immunity, September 2002, p. 5036-5044, Vol. 70, No. 9
0019-9567/02/$04.00+0 DOI: 10.1128/IAI.70.9.5036-5044.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Biochemistry and Immunology and Institute for Investigation in Immunology-Millenium Institute,1 Department of General Biology, Federal University of Minas Gerais, Belo Horizonte, Brazil,2 Biotechnology Institute, Center for Veterinary Sciences Investigation-INTA, Moron, Buenos Aires, Argentina,3 Department of Animal Health and Biomedical Sciences, University of Wisconsin-Madison, Madison, Wisconsin 537064
Received 15 March 2002/ Accepted 28 May 2002
|
|
|---|
exsA mutant compared to the survival of parental strain S2308 demonstrated that ExsA is critical for full bacterial virulence. Additionally, the B. abortus exsA deletion mutant was used as a live vaccine. Challenge experiments revealed that the exsA mutant strain induced superior protective immunity in BALB/c mice compared to the protective immunity induced by strain S19 or RB51. |
|
|---|
To be successful in infection, a pathogenic intracellular bacterium requires four steps: adherence, invasion, establishment, and dissemination within the host (15). The interaction between host and pathogen also includes uptake and secretion of substances, which are facilitated by a family of proteins termed transporters. ATP-binding cassette (ABC) transporters are some of the active transport systems that are common in bacteria and eukaryotic cells (14). ABC transporters use the free energy of ATP hydrolysis to pump substances across the membrane against a concentration gradient into or out of cells (27). These transporters can use a variety of substrates, such as amino acids, sugars, inorganic ions, polysaccharides, peptides, and proteins like toxins. In Rhizobium meliloti, a member of the alpha subgroup of the Proteobacteria closely related to Brucella, the exsA gene was identified as a gene that encodes an ABC transporter of the exopolysaccharide succinoglycan (EPS I) (4). EPS I is essential for the invasion of alfalfa root nodules by R. meliloti. Mutants of R. meliloti devoid of EPS I are unable to establish an effective symbiosis with alfalfa (22). Since EPS I from R. meliloti is a surface polysaccharide, like Brucella lipopolysaccharide (LPS), which is considered an important virulence factor involved in many host-pathogen interactions (11) and therefore pathogenesis, we decided to isolate and further characterize the B. abortus exsA gene and the product that it encodes.
In this study, we identified the gene encoding B. abortus ExsA and performed a nucleotide and deduced amino acid sequence analysis. The amino acid sequence analysis revealed a high degree of identity among the B. abortus ABC transporter and R. meliloti and Mesorhizobium loti ExsA proteins. The sequence similarity and the presence of ABC transporter motifs in the Brucella ExsA sequence suggest a role for this molecule in the polysaccharide transport function critical in bacterial pathogenesis (11, 33). Furthermore, a mutant with a defined mutation in the exsA gene of B. abortus was obtained by gene replacement. The survival of the mutant was analyzed in the mouse model, and it was determined that ExsA is required for full virulence during Brucella infection. Additionally, the B. abortus
exsA mutant induced greater protective immunity in BALB/c mice than the commercially available strain S19 vaccine induced.
|
|
|---|
was cultured at 37°C in Luria-Bertani medium containing kanamycin (50 µg/ml) or ampicillin (100 µg/ml) as needed (28). |
View this table: [in a new window] |
TABLE 1. Bacterial strains and vectors used in this study
|
Determination of the exsA gene copy number in the B. abortus genome.
Genomic DNA from B. abortus strain S2308 was isolated as described previously (17). For DNA hybridization, 10 µg of genomic DNA was digested with BamHI, EcoRI, and EcoRV. BamHI and EcoRI did not cut within the open reading frame (ORF), whereas EcoRV did cut in the middle of the exsA gene. The fragments obtained were separated by 1% agarose gel electrophoresis, passively transferred onto a nylon membrane (Hybond-N; Amersham Pharmacia Biotech), and UV cross-linked. The exsA fragment was used as a DNA probe. This fragment was labeled with [
-32P]dCTP by random priming (Gibco BRL). Hybridization was performed under stringent conditions (38°C, 50% formamide) as described previously (28). The nylon membrane was subjected to autoradiography for 18 h at -80°C.
Construction of B. abortus
exsA deletion mutant.
The deletion plasmid used for exsA gene replacement in B. abortus was constructed as follows. Plasmid pUC4K (Amersham Pharmacia Biotech) was digested with EcoRI, which produced a 1.2-kb fragment containing the kanamycin resistance cassette. This DNA fragment was blunt ended with T4 DNA polymerase (Amersham Pharmacia Biotech) and ligated into the unique EcoRV site of the exsA gene present in pUC64 to generate plasmid pGR64 (Fig. 1). To prepare B. abortus S2308 competent cells, bacteria were grown in 200 ml of brucella broth for 6 h at 37°C to the log phase (optical density at 600 nm, 0.4 to 0.6). The bacterial cells were harvested by centrifugation at 5,000 x g for 10 min, and they were washed three times with cold double-distilled water plus 10% glycerol and resuspended in 0.65 ml of chilled 10% glycerol. After that, 0.05-ml aliquots were stored immediately at -80°C. Five micrograms of pGR64 plasmid DNA was added to 50 µl of B. abortus competent cells in sterile electroporation cuvettes with 0.2-cm electrode gaps (Bio-Rad Laboratories, Richmond, Calif.), and then electroporation was performed with a Gene Pulser II transfection apparatus (Bio-Rad Laboratories) at 25 µF, 2.5 kV, and 400
. One milliliter of SOC (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose; Gibco BRL Life Technologies, Inc., Gaithersburg, Md.) was added, and the cells were grown with agitation at 37°C for 16 h and plated on brucella agar containing 25 µg of kanamycin per ml. After 3 to 5 days of incubation at 37°C, transformants were examined by replica plating on brucella agar containing 25 µg of kanamycin per ml and 25 µg of ampicillin per ml. Then colonies that were Kanr Amps and Kanr Ampr were selected as colonies in which double and single crossover events had occurred, respectively.
![]() View larger version (13K): [in a new window] |
FIG. 1. Schematic map of clone 64 encoding the exsA gene of B. abortus and construction of the pGR64 target vector for generation of the exsA mutant by gene replacement. The arrow indicates the translation direction, and the cross-hatched bar indicates the exsA gene. Kanr, kanamycin resistance gene.
|
exsA deletion mutant.
To provide genetic evidence that the wild-type exsA gene was replaced by an exsA gene interrupted by the Kanr cassette, 10 µg of genomic DNA isolated from both the mutant strain and the wild-type strain (S2308) was digested with EcoRI and then loaded onto a 0.8% agarose gel to perform Southern blotting. The genomic DNA was transferred to a nylon membrane by capillary transfer overnight in 10x SSC buffer (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate). DNA bound to the membrane was exposed to UV cross-linking and then prehybridized at 42°C for 4 h in 25 ml of a prehybridization solution (6x SSC, 0.2% sodium dodecyl sulfate, 10x Denhardt's solution, 100 µg of salmon sperm per ml, 50% formamide). The exsA, Kanr, and Ampr genes were used as probes and were labeled with [
-32P]dCTP by using a random-primed labeling kit (Gibco BRL), and unincorporated 32P was removed by Sephadex G-50 column chromatography. Hybridization was conducted at 42°C in the same prehybridization solution for 16 h. The blots were washed three times with 2x SSC-0.1% sodium dodecyl sulfate at 60°C for 30 min. After the last wash, the membrane was subjected to autoradiography for 6 h at -80°C.
Survival in the mouse model.
Virulence was determined by measuring the numbers of CFU of wild-type and mutant strains in mouse spleens. Female BALB/c mice that were 6 to 8 weeks old were injected intraperitoneally (i.p.) with 1 x 105 CFU of brucellae in 0.1 ml of phosphate-buffered saline (PBS) (145 mM NaCl, 49 mM KH2PO4, 21 mM Na2HPO4; pH 7.2). Groups of eight mice were injected with either B. abortus S2308 or the B. abortus
exsA mutant strain. At 1, 2, and 6 weeks postinoculation, all mice in each group were killed, and bacterial survival was determined following homogenization of the mouse spleens in 10 ml of PBS. Tenfold serial dilutions of the homogenized spleens were plated on brucella agar containing kanamycin to determine the number of
exsA CFU per spleen compared to the number of wild-type CFU.
Immunization of mice with the B. abortus
exsA mutant.
Female BALB/c mice that were 6 to 8 weeks old were immunized i.p. with 1 x 105 CFU of brucellae in 0.2 ml of PBS. Groups containing eight mice each were immunized with either B. abortus S19, B. abortus RB51, or B. abortus
exsA. Nonimmunized, control mice were injected i.p. with 0.2 ml of PBS. Six weeks after immunization, all mice in each group were challenged by i.p. injection of 1 x 105 CFU of B. abortus S2308. Experimentally infected mice were killed 2 weeks later by cervical dislocation, and the spleens were collected and disrupted in 10 ml of PBS. Tenfold serial dilutions were plated on brucella agar containing kanamycin or 0.1% erythritol for differentiation of B. abortus
exsA, B. abortus strain S19, and B. abortus strain S2308. After 3 days of incubation at 37°C, colonies were visualized, and the number of CFU of B. abortus S2308 per spleen was determined after the number of B. abortus S19 or B. abortus
exsA found by replica plating was subtracted. The degrees of protection in immunized animals and controls were expressed as the mean CFU of B. abortus S2308 for each mouse group obtained after challenge and log10 conversion. Log10 units of protection were obtained by subtracting the mean log10 CFU for the experimental group from the mean log10 CFU for the control group, as previously described (19).
Statistical analyses. Statistical analyses were performed with Student's t test by using the MINITAB computer software package (Minitab Inc., State College, Pa.).
Nucleotide sequence accession number. The nucleotide sequence of the exsA gene of B. abortus has been deposited in the GenBank database under accession number AF218367.
|
|
|---|
![]() View larger version (73K): [in a new window] |
FIG. 2. Nucleotide sequence of the B. abortus exsA gene and deduced amino acid sequence. The asterisk indicates the termination code.
|
![]() View larger version (70K): [in a new window] |
FIG. 3. Alignment of ABC transporter protein (ExsA) amino acid sequences from R. meliloti (Rm), M. loti (Ml), and B. abortus (Ba). Three typical ABC transporter motifs, Walker A and B and the SGG (Q) ABC signature, are indicated by gray boxes. Gaps are indicated by dashes. Asterisks indicate identical residues, colons indicate conserved substitutions, and periods indicate semiconserved substitutions. The percentages of identity with the amino acid sequence of the ABC transporter protein (ExsA) from B. abortus are indicated in parentheses.
|
![]() View larger version (33K): [in a new window] |
FIG. 4. Hydrophobic profiles of ExsA proteins of B. abortus (A), R. meliloti (B), and M. loti (C). The analysis was performed by using the Kyte-Doolittle method. The vertical axis indicates the relative hydrophobicity (above the horizontal line) or hydrophilicity (below the horizontal line). The boxes indicate the potential transmembrane regions, and the numbers at the bottom are the amino acid positions.
|
exsA deletion mutant.
Before constructing a B. abortus
exsA deletion mutant, we determined the copy number of the exsA gene in B. abortus. Southern blot analysis revealed that a single copy of the exsA gene is present in the B. abortus genome (data not shown). Furthermore, a defined Kanr Amps
exsA deletion mutant of B. abortus S2308 was constructed by chromosomal gene replacement. After electroporation, transformants were examined by replica plating on brucella agar containing kanamycin and ampicillin or kanamycin alone. Ten clones of the two phenotypes, Kanr Ampr and Kanr Amps, were selected to confirm that the exsA-deficient (Kanr Amps) clones were the result of an allelic exchange. Chromosomal DNA was isolated from these clones and from the parental strain for Southern blot analysis. The same hybridization profile was observed for all transformants selected from each different phenotype group, as shown in Fig. 5. DNA hybridization of EcoRI-digested chromosomal DNA by using the exsA probe produced one fragment at approximately 4.8 kb for B. abortus S2308 (Fig. 5A, lane 4) and a 6.0-kb band for the Kanr Amps
exsA mutant (lane 1). The 1.2-kb difference between the exsA hybridizing fragment present in the Kanr Amps mutant (lane 1) and the fragment in B. abortus S2308 (lane 4) was due to insertion of the kanamycin cassette. This profile indicates that a double crossover between the deletion plasmid and homologous chromosomal DNA occurred. A single recombination event gave rise to clones (lanes 2 and 3) that produced two fragments, one that corresponded to the wild-type exsA gene and one that comprised the deletion plasmid. These two bands appeared in the Southern blot profile because the pGR64 deletion plasmid had one EcoRI restriction site present in the polylinker. This result was confirmed when the Ampr probe hybridized to only one fragment corresponding to integration of the deletion plasmid (pGR64) in the chromosome (Fig. 5B). When the kanamycin cassette was used as a probe, it hybridized to genomic DNA from Kanr Amps or Kanr Ampr clones but not to genomic DNA of wild-type B. abortus S2308, which was used as a negative control (Fig. 5C). The size difference in the fragments observed in Fig. 5C between the Kanr Amps and Kanr Ampr clones again was due to integration of the deletion plasmid in the ampicillin-resistant bacterial cells.
![]() View larger version (43K): [in a new window] |
FIG. 5. Characterization of the B. abortus exsA mutant by Southern blot analysis. EcoRI-digested genomic DNA was probed with the exsA gene (A), Ampr (B), or Kanr (C) DNA fragments. Lanes 1, B. abortus exsA mutant; lanes 2 and 3, clones in which a single recombination event took place; lanes 4, B. abortus S2308. Lanes MW contained molecular weight markers.
|
exsA mutant in BALB/c mice.
The ability of B. abortus to persist within BALB/c mice has been shown to correlate with virulence in the natural host (12). Groups of mice were inoculated i.p. with the
exsA mutant or B. abortus parental strain S2308 to determine differences in persistence in the mouse model. The Brucella CFU were evaluated 1, 2, and 6 weeks postinfection in the spleen of each animal. The B. abortus
exsA mutant strain displayed reduced virulence at all times tested compared to the virulence of the wild type (Fig. 6). The smallest difference in CFU between the
exsA mutant and S2308 was observed at week 2 (log 0.23), and the greatest difference was observed at week 6 (log 0.92). Nevertheless, the log CFU difference between these two strains was statistically significant at all times studied.
![]() View larger version (10K): [in a new window] |
FIG. 6. Persistence of B. abortus S2308 and the B. abortus exsA mutant in BALB/c mice. Eight mice were infected i.p. with a dose of 105 CFU of bacteria. Spleens were harvested at different times, and the number of CFU in disrupted tissue was determined by 10-fold serial dilution and plating. The values are means ± standard deviations. The asterisks indicate statistically significant differences between the results obtained for the group that received the mutant and the results obtained for the group that received B. abortus parental strain S2308 (P < 0.05).
|
exsA mutant strain.
To determine if the B. abortus
exsA mutant strain is able to induce protective immunity against infection, mice immunized with the
exsA mutant or with strain S19 or RB51 were challenged with the B. abortus virulent strain (S2308). The numbers of bacterial CFU in the spleens were determined 6 weeks after challenge, since Araya et al. (3) showed that nonspecific resistance to infection with unrelated bacteria is very low 6 weeks after immunization with Brucella. At this time, mice immunized with the B. abortus
exsA mutant strain had significantly (P < 0.05) fewer splenic brucellae than nonimmunized animals (Table 2). Additionally, we observed higher log units of protection in mice immunized with the
exsA mutant strain (2.74 log units) than in mice immunized with commercial vaccine strain S19 (1.44 log units) or RB51 (0.84 log unit) following challenge. Thus, the B. abortus
exsA mutant strain induced significantly enhanced resistance to experimental infection. |
View this table: [in a new window] |
TABLE 2. Protection of mice against challenge with B. abortus S2308 after immunization with the B. abortus exsA mutant or with the B. abortus S19 or RB51 vaccine strain
|
|
|
|---|
In this study, we identified, sequenced, and disrupted the exsA gene of B. abortus. The deduced amino acid sequence for the ORF from clone 64 exhibited homology to ABC transporters of different bacterial species, mainly ExsA of R. meliloti and M. loti, with which the levels of sequence identity were 69 and 67%, respectively. The ABC transporters are a major class of cellular translocation machinery in all bacterial species (32). Based on computer analysis of the predicted amino acid sequence, Walker and ABC signature motifs that could form an ATP-binding site were identified in the C-terminal domain of Brucella ExsA. Additionally, the ABC transporter transmembrane region in the highly hydrophobic segment was predicted. In R. meliloti, the exsA gene encodes an ABC transporter involved in EPS I transport (4). EPS I is essential for the invasion of alfalfa root nodules by R. meliloti. Mutants of R. meliloti devoid of EPS I are unable to establish an effective symbiosis with alfalfa (22). Since like Rhizobium and Mesorhizobium, Brucella belongs to the alpha-2 subgroup of the Proteobacteria (21), whose members are characterized by their ability to interact pericellularly or intracellularly with eukaryotic cells, we suggest that Brucella ExsA functions as a polysaccharide transporter and may be crucial for the maintenance of Brucella pathogenesis.
To address the role of Brucella ExsA in bacterial virulence, a mutant was constructed. In mice the
exsA mutant exhibited a different level of spleen colonization than wild-type strain S2308, indicating that virulence in vivo was altered by the absence of ExsA (Fig. 6). Brucella ExsA also showed a high degree of homology to the Sinorhizobium meliloti MsbA-like saccharide-exporting ABC transporter (data not shown). An msbA mutant strain of Francisella novicida, a facultatively intracellular bacterium like Brucella that survives and grows in macrophages by preventing phagolysosomal fusion, was unable to grow in macrophages and mice, and it was found to be sensitive to serum (20). Therefore, we speculate that the Brucella
exsA mutant has an altered polysaccharide architecture, as demonstrated previously for E. coli (9, 11), and therefore is sensitive to complement-mediated lysis and/or phagocyte-mediated killing mechanisms. Macrophages and neuthophils are potent killers of Brucella, and this bacterium is extremely sensitive to the myeloperoxidase-halide-peroxide system found in the host phagocyte system (7). This phenomenon has been demonstrated in B. abortus LPS mutants (1). Even though changes in polysaccharide structure enhanced bacterial clearance, the B. abortus
exsA mutant has a smooth phenotype, like parental strain S2308 (data not shown).
Besides its importance in helping understand Brucella pathogenesis, our study also could have an impact on vaccine development. Bacterial vaccines are usually based on either live or inactivated whole-cell or subunit preparations (6). Live vaccines for intracellular organisms are generally more efficacious and consist of attenuated variants of particular pathogens that have lost the ability to cause clinical disease but are still able to establish self-limiting infections and hence immune responses in the hosts (36). As genes required for intracellular growth and survival of brucellae are identified, attenuated variants harboring defined genetic defects can be evaluated. Rational genetic attenuation of a pathogen could lead to a new generation of live bacterial vaccines that are safer and do not revert to full virulence. As demonstrated here, the B. abortus
exsA mutant induced superior protective immunity compared to the protective immunity induced by the Brucella vaccine strains currently available, S19 and RB51. RB51 induced lower resistance to challenge with the pathogenic strain S2308, probably due to rapid clearance of this strain (30) and to the absence of antibodies against LPS (31). As for strain S19, we suggest that a lower level of protection was induced in mice because of more rapid bacterial clearance with this strain than with the
exsA mutant. At 6 weeks postinfection, B. abortus S19 was cleared more rapidly than the B. abortus
exsA mutant (data not shown). Ideally, a live-vaccine strain conferring solid immunity without host restrictions would be a significant improvement over available vaccines.
We thank Junko Yabuzaki and Minoru Kanehisa from Kyoto University for ABC transporter ortholog group analysis.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»